Sign in Sign up for free

Last updated: 13 May 2024 at 6:45am EST

David Norton Net Worth




The estimated Net Worth of David Y Norton is at least $464 Thousand dollars as of 29 March 2022. Mr. Norton owns over 3,384 units of Mallinckrodt Plc stock worth over $6,921 and over the last 11 years he sold MNK stock worth over $42,232. In addition, he makes $415,000 as Independent Director at Mallinckrodt Plc.

Mr. Norton MNK stock SEC Form 4 insiders trading

David has made over 5 trades of the Mallinckrodt Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 3,384 units of MNK stock worth $42,232 on 29 March 2022.

The largest trade he's ever made was selling 3,384 units of Mallinckrodt Plc stock on 29 March 2022 worth over $42,232. On average, David trades about 476 units every 66 days since 2013. As of 29 March 2022 he still owns at least 20,356 units of Mallinckrodt Plc stock.

You can see the complete history of Mr. Norton stock trades at the bottom of the page.





David Norton biography

David York Norton is Independent Director of the Company. He is chairman of the board of directors of VIVUS, Inc., where he has been a director since July 2013. Mr. Norton was company group chairman, Global Pharmaceuticals, for Johnson & Johnson, a role in which he led and developed the business’ strategic growth agenda, including the strategy for licensing, acquisitions and divestments, and ensuring alignment with the global strategic functions, research and development, and commercial organizations. He retired in 2011 from Johnson & Johnson, where his 32-year tenure spanned marketing and international country management roles; serving as president of the Janssen Pharmaceuticals business in the U.S., group chairman of the Pharmaceuticals Group for Europe, Middle East and Africa, and then for the U.S. and Canada business; as well as the role of company group chairman, worldwide commercial and operations, for Johnson & Johnson’s CNS and virology business. He previously served as a director for INC Research Holdings Inc. and Savient Pharmaceuticals Inc. Mr. Norton also serves on the board of TB Alliance, a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. Mr. Norton’s qualifications to serve on our Board include his significant experience as an executive and board member of publicly traded pharmaceutical companies.

What is the salary of David Norton?

As the Independent Director of Mallinckrodt Plc, the total compensation of David Norton at Mallinckrodt Plc is $415,000. There are 9 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.



How old is David Norton?

David Norton is 68, he's been the Independent Director of Mallinckrodt Plc since 2017. There are 1 older and 12 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.

What's David Norton's mailing address?

David's mailing address filed with the SEC is COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.

Insiders trading at Mallinckrodt Plc

Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., and Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.



What does Mallinckrodt Plc do?

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit



What does Mallinckrodt Plc's logo look like?

Mallinckrodt Plc logo

Complete history of Mr. Norton stock trades at VIVUS, Mallinckrodt Plc, and COMPASS Pathways plc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
29 Mar 2022 CMPS COMPASS Pathways plc David Y Norton
Director
 Sale 3,384 $12.48 $42,232
29 Mar 2022
20,356 ↗
10 Nov 2017 MNK Mallinckrodt Plc David Y Norton
Director
 Buy 2,000 $22.02 $44,040
10 Nov 2017
7,601 ↗
31 Oct 2016 VVUS VIVUS, Inc. David Y Norton
Director
 Option 3,125 $10.50 $32,813
31 Oct 2016
30,401 ↗
30 Sep 2016 VVUS VIVUS, Inc. David Y Norton
Director
 Option 3,125 $11.40 $35,625
30 Sep 2016
28,057 ↗
31 Aug 2016 VVUS VIVUS, Inc. David Y Norton
Director
 Option 3,125 $10.60 $33,125
31 Aug 2016
25,720 ↗


Mallinckrodt Plc executives and stock owners

Mallinckrodt Plc executives and other stock owners filed with the SEC include: